becton dickinson compani
summari host manag walk away
increas confid compani outlook
beyond result revis price target
manag sound confid deliv
compani commit confid meet goal
sale growth report double-digit ep growth
regardless lutonix btk knee statu
manag see free cash-flow plan increas
invest intern acceler tuck-in deal
invest focus acceler bdx top-lin growth
maintain double-digit ep growth expect hear
next phase growth expect manag unveil
cost containment/synergi plan next year final bcr
integr remain track despit dcb headwind
manag seem hope btk would approv eventu
manag express high degre confid
growth bdx guidanc underli sale growth
impli growth acceler nearli nearli
driven easier comp new product launch specif
manag sound confid top-lin growth
similar even slightli better
growth driver includ follow medic deliveri
solut md growth expect acceler continu
ramp hypoderm busi follow earlier suppli issu
still grow despit tough yr/yr comp
high-singl digit growth pharma system surgic
ucc urolog critic expect continu
bcr revenu synergi weight mostli
forecast ex-fx sale growth addit note
bdx us infus pump busi grew mid-teen
driven custom choos acceler system
upgrad instead accept fix tri
implement alari recal manag note
gain point share infus pump market
acknowledg acceler infus pump upgrad could
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
includ bcr acquisit start ep calcul use two method
determin impact prefer convert as-convert
assum mandatori convert prefer mandatorili convert
compani data secur llc estim reuter
continu previou page
commit growth outlook pivot year tighten opex belt emphas
commit deliv top-lin growth report double-digit ep growth next year assum
paclitaxel statu quo lutonix btk knee normal flu season factor
improv btk approv sale growth closer high-end rang
bottom-lin compani face headwind due expir gore royalti
due fx headwind china tariff underli basi bdx ep
growth would reach high-teen underli basi exclud headwind opex line
plan tighten belt decreas spend hold steadi minim increas
sales/market expens addit financi engin recent refi currenc swap
also deploy help off-set headwind bottom-lin manag commit
sound confid deliv outlook
focu next phase valu creation last sever year compani
focus two transform deal carefus cr bard integr
busi third year bcr deal model manag plan pivot focu run
compani term increas invest busi acceler tuck-in acquisit
goal improv top-lin growth sustain double-digit bottom-lin growth
addit next year expect manag unveil next phase compani
cost contain plan extract addit synergi final expect complet
bcr-relat de-lever next month free cash-flow
acceler invest would accret sale growth manag prefer focu tuck-in
opportun go forward rather anoth larg transform deal compani plan continu
pay debt expect financi capac resum share repurchas also
contribut ep growth current model sale growth ep growth
compar consensu forecast respect
manag also confid margin improv note gross margin
reflect fx headwind sale mix includ disproportion high contribut
lower-margin infus pump sale fx drag expect revers sale mix
return normal give manag confid gross margin exceed full year
guidanc rang forecast gross margin manag anticip oper
margin expans return vs due sever fx headwind
would put compani track achiev margin improv three year bcr
deal model forecast oper margin yr/yr
manag seem still hope lutonix btk knee believ recent
fda updat paclitaxel situat materi chang current landscap compani
collabor competitor draft propos label updat devic fda could
see final label updat next month manag believ could repres
inflect point minimum compani expect outlook wors post label
updat lutonix btk manag sound hope approv still possibl especi given
huge unmet medic need base posit clinic data compani meet fda
later year discuss propos supplement data submiss includ final
pivot data data european registri continu exclud lutonix btk
bcr integr synergi remain track manag note revenu cost
synergi bcr acquisit remain track despit paclitaxel headwind btk delay
busi grow year consist deal model expect continu
even without btk continu anticip revenu synergi grow
acceler addit transact ad growth
rate bdx weight end-market estim
emerg market em growth momentum continu continu view em high growth
market similar dynam five year ago much focu em remain product sale
physician train educ china specif account bdx em sale
manag expect sale growth continu low double-digit compani plan invest three
time capit china next three year last three year expand local
manufactur current legaci product manufactur local china china
becton dickinson compani
price target
price target base blend ev/ebitda ebitda price-to-earnings
estim risk includ slower expect integr bcr lower expect cost save
accret bcr unexpect delay debt pay unexpect pipelin delay/setback
believ solidli posit deliv mid-singl digit top-lin growth low double-digit
bottom-lin growth forese futur
global medic devic compani oper two key segment medic life
scienc pend bcr acquisit add third leg platform intervent grew
revenu nearli pro forma underli basi
